Public health psychopharmacology: a new research discipline comes of age?

被引:2
|
作者
Barbui, C. [1 ]
Ostuzzi, G. [1 ]
Godman, B. [2 ,3 ,4 ]
机构
[1] Univ Verona, Dept Neurosci, WHO Collaborating Ctr Res & Training Mental Hlth, Sect Psychiat, Verona, Italy
[2] Strathclyde Univ, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
[3] Univ Liverpool, Management Sch, Ctr Hlth Econ, Liverpool, Merseyside, England
[4] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Clin Pharmacol, Dept Lab Med, Stockholm, Sweden
关键词
Affordability; availability; psychotropic medicines; rational prescribing; selection of medicines; SCHIZOPHRENIA; MEDICATION; PREVALENCE; DECISIONS; TRIALS;
D O I
10.1017/S2045796017000464
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Research evidence guiding the identification of pragmatic and effective actions aimed at improving the selection, availability, affordability and rational prescribing of medicines for mental disorders is sparse and inconsistent. In order to boost the development of new research, in this commentary we suggest to organise and classify all the activities in this area under a common theoretical framework and nomenclature, adopting the term public health psychopharmacology'. Public health psychopharmacology is proposed as a research discipline, based on contributions from the fields of regulatory science, health services research and implementation science. Implementing the term public health psychopharmacology may offer advantages, as the scientific community would be more focused on common goals and objectives, with, likely, an increasing body of research evidence of practical use.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 50 条